相似文献
1
Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia.
Schizophr Bull. 2015 Sep;41(5):1003-9. doi: 10.1093/schbul/sbv036. Epub 2015 Apr 2.
2
MMP-9 in translation: from molecule to brain physiology, pathology, and therapy.
J Neurochem. 2016 Oct;139 Suppl 2:91-114. doi: 10.1111/jnc.13415. Epub 2016 Mar 21.
3
Glutamatergic Dysfunction and Synaptic Ultrastructural Alterations in Schizophrenia and Autism Spectrum Disorder: Evidence from Human and Rodent Studies.
Int J Mol Sci. 2020 Dec 23;22(1):59. doi: 10.3390/ijms22010059.
4
Matrix Metalloproteinase-9 and Synaptic Plasticity in the Central Amygdala in Control of Alcohol-Seeking Behavior.
Biol Psychiatry. 2017 Jun 1;81(11):907-917. doi: 10.1016/j.biopsych.2016.12.026. Epub 2017 Jan 5.
5
MMP9: a novel function in synaptic plasticity.
Int J Biochem Cell Biol. 2012 May;44(5):709-13. doi: 10.1016/j.biocel.2012.01.023. Epub 2012 Feb 9.
6
miR-132 Regulates Dendritic Spine Structure by Direct Targeting of Matrix Metalloproteinase 9 mRNA.
Mol Neurobiol. 2016 Sep;53(7):4701-12. doi: 10.1007/s12035-015-9383-z. Epub 2015 Aug 29.
7
Matrix metalloproteinase-9 activity increased by two different types of epileptic seizures that do not induce neuronal death: a possible role in homeostatic synaptic plasticity.
Neurochem Int. 2010 May-Jun;56(6-7):799-809. doi: 10.1016/j.neuint.2010.03.003. Epub 2010 Mar 18.
8
Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory.
J Neurosci. 2006 Feb 15;26(7):1923-34. doi: 10.1523/JNEUROSCI.4359-05.2006.
9
The extracellular matrix glycoprotein tenascin-C and matrix metalloproteinases modify cerebellar structural plasticity by exposure to an enriched environment.
Brain Struct Funct. 2017 Jan;222(1):393-415. doi: 10.1007/s00429-016-1224-y. Epub 2016 Apr 18.
10
Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity.
J Biol Chem. 2007 Jun 1;282(22):16036-41. doi: 10.1074/jbc.M700641200. Epub 2007 Apr 10.
引用本文的文献
1
Distinct effects of psychiatric disorder diagnoses and severe emotional dysregulation on matrix metalloproteinase-9, proinflammatory cytokines, and inhibitory control function in adolescents with attention-deficit hyperactivity disorder or first-episode major affective disorders.
Int J Neuropsychopharmacol. 2025 May 9;28(5). doi: 10.1093/ijnp/pyaf024.
2
Comparative Analysis of Blood MMP-9 Concentration in Alcohol- and Opioid-Addicted Patients.
Diseases. 2025 Jan 24;13(2):30. doi: 10.3390/diseases13020030.
3
Elevated plasma matrix metalloproteinase 9 in schizophrenia patients associated with poor antipsychotic treatment response and white matter density deficits.
Schizophrenia (Heidelb). 2024 Aug 27;10(1):71. doi: 10.1038/s41537-024-00494-w.
4
Variations to plasma HO levels and TAC in chronical medicated and treatment-resistant male schizophrenia patients: Correlations with psychopathology.
Schizophrenia (Heidelb). 2024 Apr 11;10(1):45. doi: 10.1038/s41537-024-00468-y.
5
Matrix metalloproteinase 9 (MMP-9) activity, hippocampal extracellular free water, and cognitive deficits are associated with each other in early phase psychosis.
Neuropsychopharmacology. 2024 Jun;49(7):1140-1150. doi: 10.1038/s41386-024-01814-5. Epub 2024 Mar 2.
6
Behavioral and transcriptional effects of repeated electroconvulsive seizures in the neonatal MK-801-treated rat model of schizophrenia.
Psychopharmacology (Berl). 2024 Apr;241(4):817-832. doi: 10.1007/s00213-023-06511-7. Epub 2023 Dec 11.
7
Genome-wide Association Analysis of Schizophrenia and Vitamin D Levels Shows Shared Genetic Architecture and Identifies Novel Risk Loci.
Schizophr Bull. 2023 Nov 29;49(6):1654-1664. doi: 10.1093/schbul/sbad063.
8
Dysregulation of Synaptic Plasticity Markers in Schizophrenia.
Indian J Clin Biochem. 2023 Jan;38(1):4-12. doi: 10.1007/s12291-022-01068-2. Epub 2022 Jul 25.
9
Disrupting interaction between miR-132 and 3'UTR improves synaptic plasticity and memory in mice.
Front Mol Neurosci. 2022 Aug 5;15:924534. doi: 10.3389/fnmol.2022.924534. eCollection 2022.
10
Collagen VI deficiency causes behavioral abnormalities and cortical dopaminergic dysfunction.
Dis Model Mech. 2022 Sep 1;15(9). doi: 10.1242/dmm.049481. Epub 2022 Sep 21.
本文引用的文献
1
Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways.
Nat Neurosci. 2015 Feb;18(2):199-209. doi: 10.1038/nn.3922. Epub 2015 Jan 19.
2
Dendritic spine alterations in schizophrenia.
Neurosci Lett. 2015 Aug 5;601:46-53. doi: 10.1016/j.neulet.2014.11.042. Epub 2014 Dec 3.
3
Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.
Cell Rep. 2014 Dec 11;9(5):1742-1755. doi: 10.1016/j.celrep.2014.10.064. Epub 2014 Nov 26.
4
Neural ECM proteases in learning and synaptic plasticity.
Prog Brain Res. 2014;214:135-57. doi: 10.1016/B978-0-444-63486-3.00006-2.
5
Synaptic plasticity mediating cocaine relapse requires matrix metalloproteinases.
Nat Neurosci. 2014 Dec;17(12):1655-7. doi: 10.1038/nn.3846. Epub 2014 Oct 19.
6
Role for MMP-9 in stress-induced downregulation of nectin-3 in hippocampal CA1 and associated behavioural alterations.
Nat Commun. 2014 Sep 18;5:4995. doi: 10.1038/ncomms5995.
7
MMPs: a novel drug target for schizophrenia.
Expert Opin Ther Targets. 2015 Jan;19(1):77-85. doi: 10.1517/14728222.2014.957672. Epub 2014 Sep 12.
8
Neuroligins, synapse balance and neuropsychiatric disorders.
Pharmacol Rep. 2014 Oct;66(5):830-5. doi: 10.1016/j.pharep.2014.04.011. Epub 2014 May 9.
9
Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Hum Psychopharmacol. 2014 Sep;29(5):483-91. doi: 10.1002/hup.2426.
10
Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.
J Neurosci. 2014 Jul 23;34(30):9867-79. doi: 10.1523/JNEUROSCI.1162-14.2014.
Zotero 插件